Physician profile
Scott Hansen Beckstead
NPI 1508810854
$3,476.44
in general payments reported to CMS, 2019-2025
40 companies · $973 in 2025
The $973 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $355 · 2023: $1,098 · 2024: $1,050 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.93 | 2023-2025 | Qulipta, Liletta, Ubrelvy |
| Abbott Laboratories | $427.06 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $370.64 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.15 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $228.01 | 2023-2025 | Veozah |
| Pfizer INC. | $177.87 | 2023-2025 | |
| Lilly USA, LLC | $153.33 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $117.93 | 2023-2024 | Spravato, Xarelto |
| Novo Nordisk INC | $104.11 | 2023-2025 | Rybelsus, Wegovy, Ozempic |
| Janssen Biotech, INC. | $91.39 | 2022-2023 | Stelara |
| Exact Sciences Corporation | $82.93 | 2023-2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $76.84 | 2022-2023 | Dupixent |
| Dynavax Technologies Corporation | $71.75 | 2023-2025 | Heplisav-B |
| Shield Therapeutics INC | $61.84 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.89 | 2022-2023 | Relistor, Xifaxan |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.78 | 2022-2025 | Gardasil 9, Enflonsia, Capvaxive |
| Redhill Biopharma INC. | $52.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.33 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $45.09 | 2023 | Trudhesa |
| Nestle Healthcare Nutrition INC. | $44.45 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $44.12 | 2024-2025 | |
| Axsome Therapeutics, INC. | $42.45 | 2023-2025 | Auvelity, Sunosi |
| Organon LLC | $37.90 | 2024-2025 | Nexplanon |
| Qol Medical, LLC | $36.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.24 | 2023-2025 | Farxiga |
| Phathom Pharmaceuticals, INC. | $30.14 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $23.32 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Tris Pharma INC | $22.49 | 2024 | Dyanavel Xr |
| Seqirus USA INC | $21.22 | 2024 | Flucelvax, Fluad |
| Supernus Pharmaceuticals, INC. | $20.67 | 2023 | Qelbree |
| Lucid Diagnostics INC. | $20.11 | 2024 | |
| Braintree Laboratories, INC. | $18.31 | 2022 | |
| Becton, Dickinson and Company | $18.02 | 2024 | Bd Surepath Collection Vial |
| Currax Pharmaceuticals LLC | $16.37 | 2023 | Contrave |
| Dexcom, INC. | $16.20 | 2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $15.93 | 2024 | |
| Amgen INC. | $14.84 | 2024 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $14.56 | 2024 | Quviviq |
| Sumitomo Pharma America, INC. | $14.49 | 2023 | Gemtesa |
| Baxter Healthcare | $13.84 | 2023 | Hillrom - Life 2000 Ventilation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Beckstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.